治疗外周T细胞淋巴瘤的新型药物课件

Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,11/24/2020,PROPEL ESMO Slides Draft,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Forth Level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,11/24/2020,PROPEL ESMO Slides Draft,#,Click to edit the title text format,Click to edit the outline text format,Second Outline Level,Third Outline Level,Fourth Outline Level,Fifth Outline Level,Sixth Outline Level,Seventh Outline Level,Eighth Outline Level,Ninth Outline Level,Click to edit the title text format,Click to edit the outline text format,Second Outline Level,Third Outline Level,Fourth Outline Level,Fifth Outline Level,Sixth Outline Level,Seventh Outline Level,Eighth Outline Level,Ninth Outline Level,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,11/24/2020,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,11/24/2020,#,治疗外周,T,细胞淋巴瘤的新型药物,治疗外周T细胞淋巴瘤的新型药物,2,2,3,3,外周,T,细胞淋巴瘤及其治疗现状,外周,T,细胞淋巴瘤（,Peripheral T-cell lymphoma,，,PTCL,）是一组起源于成熟,T,细胞、具有高度异质性的非霍奇金淋巴瘤疾病,多数,PTCL,亚型属于侵袭性淋巴瘤，预后远比,B,细胞,NHL,差,PTCL,在我国发病率约占所有,NHL,的,29.6,39.1%,，远高于西方国家，中位生存期大约,2,年，,5,年总体生存率仅,25-30%,之间；,现有治疗手段疗效持续时间短且不良反应严重，难治性复发患者缺乏有效治疗手段,2014,版,NCCN,指南对无论初诊还是复发难治性,PTCL,，纳入临床试验仍是现行治疗方案中重要的一个选择，也反映了这类疾病的临床治疗效果迫切需要改善,4,外周T细胞淋巴瘤及其治疗现状外周T细胞淋巴瘤（Periphe,PTCL,在现行治疗手段下的预后情况在所有恶性肿瘤中属于较差,其中晚期,NK/T,淋巴瘤的预后更差,PTCL,患者预后,PTCL,亚型,5-Year OS,%,IPI 0/1,IPI 4/5,外周,T,细胞淋巴瘤,-,非特指,PTCL-NOS,32,50,11,血管免疫母细胞淋巴瘤,Angioimmunoblastic,32,56,25,鼻腔,NK/T,细胞淋巴瘤,Nasal NKTCL,42,57,0,鼻外,NK/T,细胞淋巴瘤,Extranasal NKTCL,9,17,20,成人,T,淋巴母细胞淋巴瘤,ATLL,14,28,7,ALK,阳性间变性大细胞淋巴瘤,ALCL,ALK+,70,90,33,ALK,阴性间变性大细胞淋巴瘤,ALCL,ALK,49,74,13,肠病型,T,细胞淋巴瘤,Enteropathy-type,20,29,14,原发皮肤间变性大细胞淋巴瘤,Primary cutaneous ALCL,90,100,NA,肝脾,T,细胞淋巴瘤,Hepatosplenic,7,0,0,皮下脂膜炎样,T,细胞淋巴瘤,Subcutaneous panni